News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
13,427 Results
Type
Article (762)
Company Profile (19)
Press Release (12646)
Multimedia
Podcasts (2)
Webinars (2)
Section
Business (4485)
Career Advice (17)
Deals (653)
Drug Delivery (2)
Drug Development (2333)
Employer Resources (2)
FDA (215)
Job Trends (275)
News (7226)
Policy (380)
Tag
Academia (37)
Accelerated approval (2)
Adcomms (5)
Allergies (6)
Alliances (1213)
ALS (1)
Alzheimer's disease (12)
Antibody-drug conjugate (ADC) (16)
Approvals (208)
Artificial intelligence (5)
Autoimmune disease (3)
Bankruptcy (4)
Best Places to Work (218)
BIOSECURE Act (5)
Biosimilars (1)
Biotechnology (15)
Bladder cancer (1)
Brain cancer (1)
Cancer (86)
Cardiovascular disease (10)
Career advice (10)
CAR-T (12)
CDC (1)
Cell therapy (44)
Clinical research (1822)
Collaboration (43)
Compensation (27)
Complete response letters (2)
COVID-19 (103)
CRISPR (6)
C-suite (24)
Cystic fibrosis (1)
Data (103)
Diabetes (7)
Diagnostics (32)
Drug discovery (5)
Drug pricing (1)
Earnings (1460)
Editorial (2)
Employer resources (2)
Events (2469)
Executive appointments (47)
FDA (267)
Funding (39)
Gene editing (10)
Gene therapy (31)
GLP-1 (19)
Government (52)
Guidances (5)
Healthcare (385)
Immunology and inflammation (8)
Infectious disease (104)
Inflammatory bowel disease (8)
Intellectual property (6)
Interviews (3)
IPO (362)
Job creations (62)
Job search strategy (10)
Kidney cancer (1)
Labor market (4)
Layoffs (18)
Legal (65)
Liver cancer (2)
Lung cancer (9)
Lymphoma (16)
Machine learning (1)
Management (1)
Manufacturing (20)
MASH (2)
Medical device (64)
Medtech (64)
Mergers & acquisitions (315)
Metabolic disorders (14)
Neurodegenerative disease (7)
Neuroscience (25)
NextGen: Class of 2025 (139)
Non-profit (19)
Now hiring (1)
Obesity (5)
Opinion (1)
Ovarian cancer (1)
Pain (9)
Pancreatic cancer (1)
Parkinson's disease (4)
Patents (11)
Patient recruitment (6)
People (1723)
Pharmacy benefit managers (1)
Phase I (827)
Phase II (892)
Phase III (528)
Pipeline (71)
Policy (12)
Postmarket research (25)
Preclinical (282)
Press Release (1)
Prostate cancer (3)
Psychedelics (1)
Radiopharmaceuticals (2)
Rare diseases (21)
Real estate (115)
Recruiting (1)
Regulatory (351)
Reports (3)
Research institute (63)
Resumes & cover letters (3)
RSV (1)
Schizophrenia (3)
Series A (11)
Series B (4)
Service/supplier (1)
Sickle cell disease (1)
Special edition (2)
Spinal muscular atrophy (1)
Sponsored (2)
Startups (105)
Supply chain (2)
Tariffs (2)
The Weekly (2)
Vaccines (16)
Venture capital (2)
Weight loss (3)
Date
Today (3)
Last 7 days (14)
Last 30 days (77)
Last 365 days (846)
2025 (653)
2024 (1029)
2023 (1262)
2022 (1594)
2021 (1624)
2020 (1242)
2019 (731)
2018 (540)
2017 (661)
2016 (546)
2015 (591)
2014 (397)
2013 (339)
2012 (292)
2011 (296)
2010 (310)
Location
Africa (14)
Asia (1097)
Australia (91)
California (399)
Canada (104)
China (24)
Colorado (2)
Connecticut (9)
Delaware (9)
Europe (1287)
Florida (23)
Idaho (1)
Illinois (7)
India (4)
Indiana (1)
Japan (13)
Maryland (57)
Massachusetts (189)
Michigan (4)
Minnesota (4)
Nevada (1)
New Jersey (63)
New Mexico (1)
New York (34)
North Carolina (16)
Northern California (155)
Oklahoma (1)
Pennsylvania (61)
South America (9)
Southern California (154)
Texas (31)
United States (910)
Utah (2)
Washington D.C. (2)
Washington State (14)
Wisconsin (2)
13,427 Results for "barinthus biotherapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases
October 1, 2025
·
19 min read
Press Releases
Barinthus Biotherapeutics’ CEO Bill Enright to Present at the Investor Summit Virtual on June 10, 2025
June 9, 2025
·
2 min read
Press Releases
Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11
March 6, 2025
·
1 min read
Press Releases
Barinthus Bio Reports Second Quarter 2025 Financial Results and Updates on Corporate Developments
August 8, 2025
·
12 min read
Press Releases
Barinthus Bio Reports First Quarter 2025 Financial Results and Updates on Corporate Developments
May 7, 2025
·
14 min read
Press Releases
Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments
March 20, 2025
·
16 min read
Business
Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments
Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, announced its financial results for the year ended December 31, 2023, and an overview of the Company’s progress.
March 20, 2024
·
14 min read
Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024
Barinthus Biotherapeutics plc (NASDAQ: BRNS) (the Company) today announced clinical data from the Company’s hepatitis B-focused immunotherapeutic candidate, VTP-300, will be highlighted in poster and oral presentations at the European Association for the Study of the Liver (EASL) Congress, taking place June 5-8, 2024, in Milan, Italy.
May 22, 2024
·
7 min read
Business
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer, announced its financial results for the first quarter of 2024 and provided an overview of the Company’s progress.
May 13, 2024
·
13 min read
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates, today announced plans to prioritize its pipeline to focus on the development of VTP-300 in CHB and VTP-1000 in celiac disease.
June 12, 2024
·
6 min read
1 of 1,343
Next
